Custom Search

Friday, January 2, 2009

Cell Recycling Protects Tumor Cells From Anti-cancer Therapy

Cells have their own recycling system: Discarded cellular components, from individual proteins through to whole cellular organs, are degraded and the building blocks re-used in a different place. The scientific term for this recycling process is autophagy. In severely damaged cells, autophagy can also be a form of programmed cell death. In this case, the cell uses the mechanism for complete self-decomposition.

Cancer cells, too, make use of autophagy -- especially after radiation or chemotherapy. However, why autophagy is activated in this context, is not clear. It is possible that the process contributes to the death of the treated tumor cells. But autophagy might also be an attempt by the cells to survive. "Autophagy is also switched on specifically, for example, when the cell does not have enough nutrients at its disposal," explains Professor Ingrid Herr, head of the Research Group "Molecular OncoSurgery" of the German Cancer Research Center.

Working together with Dr. Anja Apel and scientists of the University of Tübingen, Ingrid Herr has studied the role of autophagy in cancer treatment. To this end, the investigators switched off a number of genes in tumor cells that are essential for autophagy. Subsequently, they irradiated the cells and then examined how many cells had survived the treatment. They found out that cells that had been almost completely resistant to radiation became more sensitive to radiotherapy due to blocked autophagy.

No effect was found on cancer cells that had already responded well to radiotherapy before. Therefore, the researchers assume that highly aggressive cancer cells use autophagy to resist tumor therapy. The Heidelberg researchers will now investigate whether blocking the recycling system might be useful to support anti-cancer therapies.

Journal reference: Anja Apel, Ingrid Herr, Heinz Schwarz, H. Peter Rodemann, Andreas Mayer. Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy. Cancer Research 2008, DOI: 10.1158/0008-5472.CAN-07-0562


Adapted from materials provided by Helmholtz Association of German Research Centres, via EurekAlert!, a service of AAAS.

Major Advance In Cancer Radiotherapy

Radical improvements in outcome for many cancer sufferers are in prospect following one of the most significant advances in radiotherapy since x-rays were first used to treat a tumour in 1904. The use of charged particles as an alternative to x-ray or gamma ray radiation can extend the scope of radiotherapy to tumours previously requiring invasive surgery, while speeding up diagnosis and reducing collateral damage to surrounding tissue.

This fast emerging field of charged particle cancer therapy was thrashed out at a recent workshop organised by the European Science Foundation (ESF), which discussed new instruments that will lead to improvements in both diagnosis and treatment. Diagnosis and treatment are closely linked in radiotherapy, since more accurate location of tumour cells in turn enables the radiation dose to be more precisely focused.

"Developments in imaging have allowed improvements in radiation beam placement, and the two areas tend to go together," said Barbara Camanzi, convenor of the ESF workshop, and specialist in radiotherapy instrumentation at the Rutherford Appleton Laboratory Department of Particle Physics near Oxford in the UK. This in turn improves prospects of destroying the tumour while reducing collateral damage to healthy tissue nearby. Such collateral damage causes not just tissue death, but can lead to induction of secondary tumours, which has been a long standing problem for traditional radiotherapy using x rays. Some tissue cells close to the tumour receive enough radiation to trigger mutations in their DNA that can cause them to become malignant, but not enough radiation to kill them. "The fall in collateral radiation deposition in the body ranges from a factor of 2 to 15 depending on the precise treatment indication and body site," noted Bleddyn Jones, an oncologist attending the ESF workshop, from the Gray Institute for Radiation Oncology and Biology in Oxford, UK. "All techniques using external gamma rays and x-rays impart a larger dose to surrounding healthy tissue with long term risks of functional changes and malignant induction."

The improved imaging made possible by use of charged particles also makes it easier to detect tumours when they are small, improving prospects for patients whether or not they actually undergo radiotherapy. "Making an earlier diagnosis of a smaller cancer increases the chance of cure following either particle beam therapy or surgery," said Camanzi.

However, the ESF workshop identified that further significant improvements in instrumentation were required, both for treatment and diagnosis, to exploit the full potential of charged particles for cancer therapy. Further work was also required to adjust dose to minimise the risk of secondary tumour formation caused by the radiation, which remains a risk with use of charged particles. The ESF workshop also addressed the need for improved design of the gantry systems used both for imaging and to deliver the radiation doses in treatment.

The other important issue addressed by the ESF workshop is educating radiotherapy consultants in the new techniques so that they are in a position to determine the best form of treatment for each individual case. Sometimes charged therapy may be the best method, in other cases traditional x-ray therapy, and in yet others surgery or chemotherapy, or combinations of these.

"There is a need to hold more educational and training meetings on particle therapy especially in those European countries that at present have no plans for such facilities," said Camanzi, who noted that a follow up symposium in Oxford had been proposed for 2010.


Adapted from materials provided by European Science Foundation.

Speedier Precise Cancer Radiotherapy Now Available

The University of Alabama at Birmingham (UAB) this month became the first U.S. medical center to offer a speedier cancer radiation therapy. The new technique can turn a 20-minute radiotherapy session into a 90-second session for selected patients.
Additionally, the new therapy saves healthy human tissue from unwanted radiation exposure at rates that are the same or better than other radiotherapy techniques, according to doctors at the UAB Comprehensive Cancer Center.

The new therapy is called RapidArc, which is the next-generation of intensity-modulated radiation therapy (IMRT). Conventional IMRT was introduced in the 1990s as a way to deliver multiple beams of radiation to a tumor, and minimize damage to nearby healthy tissues. RapidArc is an advancement on the earlier technology with radiation delivery times up to eight times faster than conventional IMRT, said the system's manufacturer Varian Medical Systems, Inc.

Varian technicians added the RapidArc capability to UAB's existing IMRT machine during the last week of April. The upgrades serve as a kind of guidance system, much like a jet's automatic pilot, so that IMRT delivery can happen during a single rotation of the machine's arm around the patient.

The first U.S. patient to be given the new therapy is an Alabama man with early-stage prostate cancer whose treatment started May 6, Fiveash said. Faster radiation delivery times reduce the chances that a slight move will affect the accuracy of the radiotherapy targeting. Also, it means patients spend less time and feel less discomfort in the treatment room, he said.

The new system incorporates powerful computers to help doctors arrive at a radiotherapy treatment strategy after pouring over thousands of biological and mathematical variables, including medical scans of each patient's tumor.


Adapted from materials provided by University of Alabama at Birmingham.

Modulated Radiotherapy Can Cut Treatment Time For Cancer Of The Rectum Without Increasing Toxicity

Application of modulated radiotherapy in the treatment of bowel cancer can enhance the results obtained by means of other conventional therapies. The technique has managed to apply the radiation in a way most adapted to the tumoral volume and risk areas, while minimising irradiation to healthy tissue. This radiotherapy procedure involves the administration of higher daily doses of radiation but with a total dose equivalent to conventional ones.

In this way the treatment time is cut by 30%, without a rise in side effects and with very high rates of pathological response.

These were the results of the study undertaken by a team of doctors at the University Hospital of Navarra, recently published in the specialist scientific journal, “International Journal of Radiation Oncology, Biology, Physics” of the American Society for Therapeutic Radiotherapy and Oncology. Involved in the research was a medical team from the area of digestive system tumours, led by Doctor José Javier Aristu, specialist at the Oncological Radiology Service. The article in the North American journal is the first published in the world giving clinical results from the application of preoperational modulated radiotherapy in tumours of the rectum.

Novelty for cancer of the rectum

IMRT (Intensity-Modulated Radiation Therapy) is a radiotherapy technique in which the administration of the radiation doses for the patient is effected by means of a lineal accelerator equipped with a system of multilaminas. Depending on the characteristics of the region that has to be irradiated, the planning system is capable of adapting high radiation doses to the shape of the target volume, enabling adjustments to be made to the morphology of the area to be treated in an individualized manner.

To date, the application of this procedure had been fundamentally limited to tumours located in the head, neck and prostrate gland. “This technique had been used in more confined tumours, more limited and smaller. We have now also begun to apply it to tumours of the rectum given that the conventional treatment, combining chemotherapy and radiotherapy, may cause high levels of toxicity”, explained Doctor Aristu.

The main goal in administering modulated radiotherapy in the treatment of cancer of the rectum, lies in excluding the greatest possible proportion of healthy tissue from the field of radiation, mainly the intestines, bladder and the healthy section of the rectum. We have shown that treatment using conventional radiotherapy and chemotherapy simultaneously causes about a 30% enteritis rate (inflammation of the intestine). However, in the study, we observed that the application of modulated radiotherapy reduces the rate of enteritis practically to the minimum in the patient who is being treated for bowel cancer. Moreover, on limiting the radiation to the tumoral mass and thus affecting healthy tissue less, it was possible to increase the daily dosage and cut the overall treatment time by approximately 30%, while the total dose administered is equivalent to two conventional treatments.

Study in phase I-II

This research, initially undertaken with 20 patients with cancer of the rectum, is in study phase I-II, the main purpose of which is to find the highest dose that can be applied using modulated radiotherapy in combination with chemotherapy. According to Doctor Aristu, the research showed for the first time that a radiation dose equivalent to that administered using conventional techniques can be applied using IMRT – in less time and with very promising rates of pathological response.


Adapted from materials provided by Basque Research.

Nanoparticles Delivering Drugs Can Kill Skin, Breast Cancer Cells

Researchers in Pennsylvania are reporting for the first time that nanoparticles 1/5,000 the diameter of a human hair encapsulating an experimental anticancer agent, kill human melanoma and drug-resistant breast cancer cells growing in laboratory cultures.

The discovery could lead to the development of a new generation of anti-cancer drugs that are safer and more effective than conventional chemotherapy agents, the scientists suggest.

The research is scheduled for the Dec. 10 issue of ACS' Nano Letters, a monthly journal.

In the new study, Mark Kester, James Adair and colleagues at Penn State's Hershey Medical Center and University Park campus point out that certain nanoparticles have shown promise as drug delivery vehicles. However, many of these particles will not dissolve in body fluids and are toxic to cells, making them unsuitable for drug delivery in humans. Although promising as an anti-cancer agent, ceramide also is insoluble in the blood stream making delivery to cancer cells difficult.

The scientists report a potential solution with development of calcium phosphate nanocomposite particles (CPNPs). The particles are soluble and with ceramide encapsulated with the calcium phosphate, effectively make ceramide soluble. With ceramide encapsulated inside, the CPNPs killed 95 percent of human melanoma cells and was "highly effective" against human breast cancer cells that are normally resistant to anticancer drugs, the researchers say.

Penn State Research Foundation has licensed the calcium phosphate nanocomposite particle technology known as "NanoJackets" to Keystone Nano, Inc. MK and JA are CMO and CSO, respectively.


Journal reference:

  1. Kester et al. Calcium Phosphate Nanocomposite Particles for In Vitro Imaging and Encapsulated Chemotherapeutic Drug Delivery to Cancer Cells. Nano Letters, 2008; 8 (12): 4116 DOI: 10.1021/nl802098g
Adapted from materials provided by American Chemical Society, via EurekAlert!, a service of AAAS.

Grape-seed Extract Kills Laboratory Leukemia Cells, Proving Value Of Natural Compounds

An extract from grape seeds forces laboratory leukemia cells to commit cell suicide, according to researchers from the University of Kentucky. They found that within 24 hours, 76 percent of leukemia cells had died after being exposed to the extract.

The investigators, who report their findings in the January 1, 2009, issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, also teased apart the cell signaling pathway associated with use of grape seed extract that led to cell death, or apoptosis. They found that the extract activates JNK, a protein that regulates the apoptotic pathway.

While grape seed extract has shown activity in a number of laboratory cancer cell lines, including skin, breast, colon, lung, stomach and prostate cancers, no one had tested the extract in hematological cancers nor had the precise mechanism for activity been revealed.

"These results could have implications for the incorporation of agents such as grape seed extract into prevention or treatment of hematological malignancies and possibly other cancers," said the study's lead author, Xianglin Shi, Ph.D., professor in the Graduate Center for Toxicology at the University of Kentucky.

"What everyone seeks is an agent that has an effect on cancer cells but leaves normal cells alone, and this shows that grape seed extract fits into this category," he said.

Shi adds, however, that the research is not far enough along to suggest that people should eat grapes, grape seeds, or grape skin in excess to stave off cancer. "This is very promising research, but it is too early to say this is chemo-protective."

Hematological cancers – leukemia, lymphoma and myeloma – accounted for an estimated 118,310 new cancer cases and almost 54,000 deaths in 2006, ranking these cancers as the fourth leading cause of cancer incidence and death in the U.S.

Given that epidemiological evidence shows that eating vegetables and fruits helps prevent cancer development, Shi and his colleagues have been studying chemicals known as proanthocyanidins in fruits that contribute to this effect. Shi has found that apple peel extract contains these flavonoids, which have antioxidant activity, and which cause apoptosis in several cancer cell lines but not in normal cells. Based on those studies, and findings from other researchers that grape seed extract reduces breast tumors in rats and skin tumors in mice, they looked at the effect of the compound in leukemia cells.

Using a commercially available grape seed extract, Shi exposed leukemia cells to the extract in different doses and found the marked effect in causing apoptosis in these cells at one of the higher doses.

They also discovered that the extract does not affect normal cells, although they don't know why.

The researchers then used pharmacologic and genetic approaches to determine how the extract induced apoptosis. They found that the extract strongly activated the JNK pathway, which then led to up-regulation of Cip/p21, which controls the cell cycle.

They checked this finding by using an agent that inhibited JNK, and found that the extract was ineffective. Using a genetic approach – silencing the JNK gene – also disarmed grape seed extract's lethal attack in leukemia cells.

"This is a natural compound that appears to have relatively important properties," Shi said.


Adapted from materials provided by American Association for Cancer Research.